Oxurion NVLeuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical firm creating subsequent technology customary of care ophthalmic therapies, with a medical stage portfolio in vascular retinal problems, will probably be presenting knowledge from Half A of its two-part Part 2 Medical Trial (“KALAHARI”) assessing THR-149 for remedy of diabetic macular edema (DME) on the upcoming Angiogenesis, Exudations, and Degeneration 2022 Assembly being held nearly on February 11-Twelfth. THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new customary of look after the 40-50% of DME sufferers displaying suboptimal response to anti-VEGF remedy.Particulars of the presentation:TITLE: Part 2 Outcomes of THR-149 in Sufferers with DME: KALAHARI Examine Half APRESENTER: Arshad M. Khanani, MD, MA, Managing Companion, Director of Medical Analysis, Director of Fellowship – Sierra Eye Associates; Medical Affiliate Professor on the College of Nevada, Reno, NVPRESENTATION DATE AND TIME: Saturday, February 12, 2022, 12:00 pm ET.ENDFor additional data please contact:About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm creating subsequent technology customary of care ophthalmic therapies, that are designed to higher protect imaginative and prescient in sufferers with retinal vascular problems together with diabetic macular edema (DME), the main reason for imaginative and prescient loss in diabetic sufferers worldwide in addition to different circumstances, together with moist age-related macular degeneration (wAMD) and retinal vein occlusion (RVO).Story continuesOxurion is aiming to construct a number one world franchise within the remedy of retinal vascular problems based mostly on the profitable improvement of its two novel therapeutics:THR-687 is a extremely selective pan-RGD integrin antagonist that’s initially being developed as a possible first line remedy for DME sufferers. Constructive topline ends in a Part 1 medical research assessing THR-687 as a remedy for DME had been introduced in 2020. Oxurion is presently conducting a Part 2 medical trial (“INTEGRAL”) evaluating THR-687 in sufferers with DME. THR-687 additionally has the potential to ship improved remedy outcomes for sufferers with wAMD and RVO.THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new customary of look after the 40-50% of DME sufferers displaying suboptimal response to anti-VEGF remedy. THR-149 has proven optimistic topline Part 1 outcomes for the remedy of DME. The corporate is presently conducting a Part 2 medical trial (“KALAHARI”) evaluating a number of injections of THR-149 in DME sufferers beforehand displaying a suboptimal response to anti-VEGF remedy. Following optimistic knowledge from Half A of this Part 2 trial (dose choice), the Firm has initiated Half B of the trial.Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels change below the image OXUR. Extra data is obtainable at www.oxurion.com.Vital details about forward-looking statementsCertain statements on this press launch could also be thought-about “forward-looking”. Such forward-looking statements are based mostly on present expectations, and, accordingly, entail and are influenced by numerous dangers and uncertainties. The Firm due to this fact can’t present any assurance that such forward-looking statements will materialize and doesn’t assume an obligation to replace or revise any forward-looking assertion, whether or not because of new data, future occasions, or every other motive. Extra data regarding dangers and uncertainties affecting the enterprise and different elements that might trigger precise outcomes to vary materially from any forward-looking assertion is contained within the Firm’s Annual Report. This press launch doesn’t represent a suggestion or invitation for the sale or buy of securities or belongings of Oxurion in any jurisdiction. No securities of Oxurion could also be provided or offered inside the US with out registration below the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any relevant U.S. state securities legal guidelines.